Glutamate (Metabotropic) Group III Receptor Antagonists
| Cat. No. | Product Name / Activity |
|---|---|
| 0972 | CPPG |
| Potent group III mGlu antagonist | |
| 1209 | LY 341495 |
| Group II/III antagonist | |
| 0711 | MAP4 |
| Selective group III mGlu antagonist; also potent group II/group III mGlu agonist | |
| 0853 | MPPG |
| Group III and group II mGlu antagonist; more selective for group III than group II | |
| 0803 | MSOP |
| Specific group III mGlu antagonist | |
| 1369 | UBP1112 |
| Group III mGlu antagonist | |
| 5248 | XAP 044 |
| Potent and selective mGlu7 antagonist |
Our Pain guide highlights over 280 products for Pain research.
Request copyRequest PDF
Our Metabotropic Glutamate Receptor review gives an overview of the pharmacological ligands used to study the mGlu receptors.
Request copyRequest PDF
Written by Prof David Nutt, this poster summarizes the brain circuits and neurotransmitter systems that are affected by the main classes of addictive drugs.
Request copyDownload PDF
Written by Alsa Pitkänen and Xavier Ekolle Ndode-Ekane, this poster summarizes current knowledge about how epilepsy develops.
Request copyDownload PDFWritten by Clea Warburton and Zafar Bashir
Our Learning and Memory poster gives an overview of the cellular mechanisms underlying recognition memory and its links to long-term depression.
Request copyDownload PDFWritten by Anthony H.V. Schapira
Our Parkinson's disease (PD) poster summarizes the neurobiology of the disease, and highlights current therapeutic treatments for symptomatic PD.
Request copyDownload PDFWritten by Justin M. Saunders and Javier González-Maeso
Our Schizophrenia poster highlights the targets and pathways representing the most promising strategies to pursue for novel drug development.
Request copyDownload PDF